Icon

STEGLUJAN (nda209805)- (5MG;EQ 100MG BASE,15MG;EQ 100MG BASE)

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE MSD SUB MERCK
5MG;EQ 100MG BASE,15MG;EQ 100MG BASE
No No
2030-Oct-21 2022-Dec-19
None None
None No
STEGLUJAN is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
0 0 0
Total Other Developers 4
Drugs with Suitability No
5MG;EQ 100MG BASE ** ** - - -
15MG;EQ 100MG BASE ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.